Novozymes A/S B(0Q4U)
DKK --+0.00%
Reward53Moderate
Risk19Low
📊50%Data
0Q4U
+0.0 · +0.00%
DKK · LSE
Novozymes A/S B |
Balanced
Market Cap:93.31Bn
ℹ️
Reward Rating
53
Moderate
Bottom 50% (model universe)
50% data coverage
ℹ️
Risk Rating
19
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0Q4U to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: kr429.87.

What is Novozymes A/S B?

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America.

0Q4U · Verdict

Moderate reward · low risk

0Q4U stands out on cash flow and balance sheet, but watch the profitability signal.

Based on 75% data coverage

0Q4U · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow95/100

    Top decile vs peers

  • Balance sheet80/100

    Current ratio 1.33

  • Volatility65/100

    Above average

Watchouts 1

  • Profitability39/100

    5% return on equity

Model-based scoring. For information only — not financial advice.

What is Novozymes A/S B?

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company is listed on the LSE in UK, with a market capitalisation of 93.31B.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (53)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap93.31B
P/E RatioN/A
Dividend Yield0.19%
52 Week High480.6386
52 Week Low333.4326
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees10,933
IndustryN/A
ExchangeLSE
Beta0.65
CurrencyDKK